One thing everyone seems to overlook is HTW has R&D ongoing in its next generation device the MVAD.There is no chance of them being left behind. The HeartWare MVAD
Next Generation Miniaturised Technology
HeartWare's MVAD program - based around a proprietary miniaturisation platform - aims to ensure that HeartWare remains at the forefront of innovation in the LVAD sector, with an evolving family of implantable miniaturised devices.
The first MVAD prototype is a full-output axial flow pump with a fully suspended rotor and a volume approximately one tenth that of the HVAD. The device commenced animal studies in August 2005. Human clinical trials are expected within approximately two years.
Further iteration of the MVAD technology is expected to lead to even smaller devices, implanted intravascularly using a catheter based procedure. Prototype work is underway for the intravascular pump.
HTW Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
